semaglutide and cardiac risk in Cardiometabolic Diseases: SELECTing the Target Population SELECT Trial

Findings: In this randomized, double-blind clinical trial of 1458 patients with chronic kidney disease stage 4 or 5, which was stopped early due to lack of efficacy, low-dose rivaroxaban did not reduce major adverse cardiovascular events (22.6% in the rivaroxaban group and 20.7% in the placebo group)

This dual activation means greater appetite suppression, improved blood sugar control, and enhanced calorie burning

But here the story takes a dispiriting turn

Naltrexone-Bupropion (Contrave) Combination Appetite and Reward Pathway Medication Administration : Oral tablets, taken twice daily

Builes-Montao has received consulting and speaking fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Janssen, Chiesi, Abbott, and Boehringer Ingelheim, and is a shareholder of Festina Lente

Genetic variations in GIPR (rs1800437), and metabolic genes like FTO and MC4R influence how individuals respond to dual receptor agonists